Evidence map›Paper›PMID 33634139›Full record

ReviewFrontiers in cell and developmental biology2021

Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update.

Luise Müller, Antje Tunger, Manja Wobus, Malte von Bonin, Russell Towers, Martin Bornhäuser, Francesco Dazzi, Rebekka Wehner, Marc Schmitz

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 3 syntheses or guidelines pooled it, 196 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Oxidative Phosphorylation and Fatty Acid Oxidation Are Central to Mitochondrial Metabolism Rewiring in CML Stem/Progenitor Cell Survival.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  9. Review
  10. [Research advances in mesenchymal stem cell therapy for graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Luise MüllerInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
Antje TungerInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
Manja WobusDepartment of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Malte von BoninNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.
Russell TowersDepartment of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Martin BornhäuserNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.
Francesco DazziSchool of Cancer and Pharmacological Sciences and KHP Cancer Research UK Centre, King's College London, London, United Kingdom.
Rebekka WehnerInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
Marc SchmitzInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.
Heidelberg University · DETU Dresden · DEUniversity Hospital Carl Gustav Carus · DEGerman Cancer Research Center · DEKing's College London · GBNational Center for Tumor Diseases · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) are characterized by an extraordinary capacity to modulate the phenotype and functional properties of various immune cells that play an essential role in the pathogenesis of inflammatory disorders. Thus, MSCs efficiently impair the phagocytic and antigen-presenting capacity of monocytes/macrophages and promote the expression of immunosuppressive molecules such as interleukin (IL)-10 and programmed cell death 1 ligand 1 by these cells. They also effectively inhibit the maturation of dendritic cells and their ability to produce proinflammatory cytokines and to stimulate potent T-cell responses. Furthermore, MSCs inhibit the generation and proinflammatory properties of CD4

Indexed as

dendritic cellsimmunomodulationmacrophagesmesenchymal stromal cellsT cells

Identifiers

PMID33634139
PMCPMC7900158
OpenAlexW3127735074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.